Dana-Farber Cancer Institute

We are working with Dr. Kim Stegmeier at Dana Farber to include myoepithelial carcinoma (MEC) in their Pediatric Cancer Dependencies (PedDep) Accelerator, a collaboration with St. Jude and the Broad Institute, which aims to uncover the unique genetic and molecular features that drive rare and pediatric cancers. PedDep Accelerator builds on the Broad Institute’s Cancer Dependency Map by systematically testing how childhood cancers respond when specific genes are turned off—revealing unique vulnerabilities that could be targeted with new therapies.

By providing our two MEC cell lines to this project, cureMEC is ensuring that MEC is represented in one of the most comprehensive efforts to chart the genetic weak points of pediatric tumors. Including MEC in the PedDep Accelerator means researchers can identify potential therapeutic targets and compare them to other rare cancers, accelerating opportunities for precision medicine.